Payments for deferred contingent consideration.

No definition available.

Name:	shpgf_PaymentsForDeferredContingentConsideration
Namespace Prefix:	shpgf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_ViropharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_NpsPharmaViropharmaAndProposedCombinationWithBaxaltaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_SarcodeBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_LumenaPharmaceuticalsIncAndLotusTissueRepairIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_SarcodeBioscienceIncAndFerrokinBioscienceIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_LumenapharmaceuticalincMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_ViropharmaSarcodeAndLotusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Integration and acquisition costs (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Integration and acquisition costs		$ 39.8	$ 158.8	$ (134.1)
Contingent consideration payments		(101.2)	(15.2)	(14.1)
Viropharma
Business Acquisition [Line Items]
Integration and acquisition costs			144.1
NPS Pharma, Viropharma, Dyax and the proposed combination with Baxalta
Business Acquisition [Line Items]
Integration and acquisition costs		189.7
SARcode
Business Acquisition [Line Items]
Change in fair value of contingent consideration				(159.1)
Lumena and Lotus Tissue Repair
Business Acquisition [Line Items]
Change in fair value of contingent consideration		(149.9)
SARcode and Ferrokin Bioscience, Inc
Business Acquisition [Line Items]
Change in fair value of contingent consideration			$ 14.7
Lumena
Business Acquisition [Line Items]
Contingent consideration payments	$ (90.0)	$ (90.0)
Viropharma, SARcode and Lotus
Business Acquisition [Line Items]
Integration and acquisition costs				$ 25.0